Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Sep;24(9 Suppl):IV1-9.
doi: 10.1002/clc.4960240902.

Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia

J Isaacsohn  1 , W Insull Jr, E Stein, P Kwiterovich, M A Patrick, R Brazg, C A Dujovne, M Shan, E Shugrue-Crowley, S Ripa, R Tota; Cerivastatin Study Group
Affiliations
Clinical Trial

Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia

J Isaacsohn et al. Clin Cardiol. 2001 Sep.

Abstract

Background: Statins are the agents of choice in reducing elevated plasma low-density lipoprotein cholesterol (LDL-C).

Hypothesis: Cerivastatin 0.8 mg has greater long-term efficacy in reducing LDL-C than pravastatin 40 mg in primary hypercholesterolemia.

Methods: In this double-blind, parallel-group, 52-week study, patients (n = 1,170) were randomized (4:1:1) to cerivastatin 0.8 mg, cerivastatin 0.4 mg, or placebo daily. After 8 weeks, placebo was switched to pravastatin 40 mg. Patients with insufficient LDL-C lowering after 24 weeks were allowed open-labeled resin therapy.

Results: Cerivastatin 0.8 mg reduced LDL-C versus cerivastatin 0.4 mg (40.8 vs. 33.6%, p <0.0001) or pravastatin 40 mg (31.5%, p<0.0001), and brought 81.8% of all patients, and 54.1% of patients with atherosclerotic disease, to National Cholesterol Education Program (NCEP) goals. Cerivastatin 0.8 mg improved mean total C (-29.0%), triglycerides (-18.3%), and high-density lipoprotein cholesterol (HDL-C) (+9.7%) (all p < or = 0.013 vs. pravastatin 40 mg). Higher baseline triglycerides were associated with greater reductions in triglycerides and elevations in HDL-C with cerivastatin. Cerivastatin was well tolerated; the most commonly reported adverse events were arthralgia, headache, pharyngitis, and rhinitis. Symptomatic creatine kinase > 10x the upper limit of normal (ULN) occurred in 1, 1.5, and 0% of patients receiving cerivastatin 0.8 mg, cerivastatin 0.4 mg, and pravastatin 40 mg, respectively. Repeat hepatic transaminases >3 x ULN occurred in 0.3-0.5, 0.5, and 0% of patients, respectively.

Conclusion: In long-term use, cerivastatin 0.8 mg effectively and safely brings the majority of patients to NCEP goal.

PubMed Disclaimer

References

    1. Levine GN, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512–521 - PubMed
    1. Riegger G, Abletshauser C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, Welzel D: The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherost lerosis 1999; 144: 263–270 - PubMed
    1. Gotto AM Jr: Assessing the benefits of lipid‐lowering therapy. Am J Cardiol 1998; 82: 2M–4M - PubMed
    1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995; 333: 1301–1307 - PubMed
    1. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB: Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419–2425 - PubMed

Publication types

MeSH terms